Which antibiotic is safer for blood infections? new study digs into Real-World data
NCT ID NCT07186894
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks back at medical records of about 5,000 people with a serious bloodstream infection caused by a common bacterium. Researchers compare two antibiotic treatments to see which one leads to better survival and fewer side effects. The goal is to find out if a newer option (cefazolin) is as good as or better than the standard penicillins.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cefazolin and antistaphylococcal penicillins (flucloxacillin, cloxacillin, oxacillin, nafcillin, dicloxacillin)
- What this could lead to
- If cefazolin proves as effective as standard penicillins with fewer side effects, it could become a preferred treatment for this serious infection.
- What could go wrong
- This is a retrospective study using existing medical records, not a controlled experiment, so results may be less reliable. Differences in patient groups could bias the findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2000
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Variables : age, sex, medical history, type of infection and antibiotic used. Variables will be described as number and percentage for categorical variables, and mean and standard-deviation for continuous ones. A propensity score matching method will be conducted including (i) variables significantly different between the two cohorts in the bivariate descriptive analyses between the patient birth and the index event date (standard difference \< 0.10 ; appendix 1), and (ii) clinically relevant variables (known confusion factors linked to mortality and safety outcomes ; appendix 2) at the index event date. Variables related to patients will be described before and after propensity score matching.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Monobacterial methicillin susceptible Staphylococcus aureus (MSSa) bacteremia * In the cefazolin group : Cefazolin injectable prescription in the week before or the week after MSSa bacteremia * In the ASPs group :ASPs injectable prescription (flucloxacillin, floxacillin, cloxacillin, oxacillin, nafcillin and dicloxacillin) in the week before or the week after MSSa bacteremia Exclusion Criteria: * In the cefazolin group : ASP injectable prescription in the year before or the year after MSSa bacteremia * In the ASPs group : cefazolin injectable prescription in the year before or the year after MSSa bacteremia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacteriemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.